AstraZeneca PLCAZN:LSE

4,042.5
82.50 / 2.08%
5.45m
19.39%
0.3392
Close in GBXToday's changeShares traded1 year changeBeta
As of Apr 23 2014 17:14 BST.Data delayed by at least 15 minutes.

Consensus recommendation

As of Apr 18, 2014, the consensus forecast amongst 49 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy4
Outperform5
Hold20
Underperform9
Sell6
No opinion0

Research Reports

Share price forecast

Share price forecast information is not available for AstraZeneca PLC. View Full Financials

Dividends

In 2013, AstraZeneca PLC reported a dividend of 2.80 USD, which represents a 1.75% decrease from last year. The 29 analysts covering the company expect dividends of 2.82 USD for the upcoming fiscal year, an increase of 0.54%. View Full Financials

Div growth (TTM)-1.75%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Feb 06, 2014, AstraZeneca plc reported 4th quarter 2013 earnings of 1.23 per share. This result exceeded the 1.16 consensus of the 13 analysts covering the company and under-performed last year's 4th quarter results by 21.15%.
The next earnings announcement is expected on Apr 24, 2014. View Full Interim Financials

Average growth rate-5.51%

AstraZeneca plc reported annual 2013 earnings of 5.05 per share on Feb 06, 2014. View Full Annual Financials

Average growth rate-4.07%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

AstraZeneca PLC had 4th quarter 2013 revenues of 6.84bn. This missed the 6.87bn consensus estimate of the 12 analysts following the company. This was 9.50% above the prior year's 4th quarter results. View Full Interim Financials

Average growth rate-1.23%

AstraZeneca PLC had revenues for the full year 2013 of 25.71bn. This was 8.09% below the prior year's results. View Full Annual Financials

Average growth rate-5.61%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.